Cronos Group (CRON) Aktievy
Cronos Group Inc. är ett cannabinoidföretag som bedriver odling, produktion, distribution och marknadsföring av cannabisprodukter i Kanada, Israel och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för CRON från våra riskkontroller.
CRON Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cronos Group Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | CA$3.75 |
| 52 veckors högsta | CA$4.66 |
| 52 veckors lägsta | CA$2.54 |
| Beta | 1.23 |
| 1 månads förändring | 4.75% |
| 3 månaders förändring | 3.31% |
| 1 års förändring | 31.12% |
| 3 års förändring | 59.57% |
| 5 års förändring | -58.19% |
| Förändring sedan börsintroduktionen | 351.81% |
Senaste nyheter och uppdateringar
Analysuppdatering • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
Analysuppdatering • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Analysuppdatering • Mar 28
CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.Analysuppdatering • Mar 13
CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Recent updates
Analysuppdatering • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.Analysuppdatering • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Analysuppdatering • Mar 28
CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.Analysuppdatering • Mar 13
CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Analysuppdatering • Feb 27
CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile
Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.Analysuppdatering • Feb 13
CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside
Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.Analysuppdatering • Jan 30
CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook
Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.Analysuppdatering • Jan 16
CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile
Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).Analysartikel • Dec 13
Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...Analysuppdatering • Sep 04
GrowCo Capacity And Global Markets Will Unlock Potential
The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).Analysartikel • Aug 15
Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
Ny analys • Apr 30
GrowCo Expansion Will Boost Operations But Strain Cash Flow
Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.Analysartikel • May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Apr 01
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...Analysartikel • Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Feb 02
Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analysartikel • Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Jul 17
We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysartikel • Jun 20
Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analysartikel • Feb 09
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Aktieägarnas avkastning
| CRON | CA Pharmaceuticals | CA Marknad | |
|---|---|---|---|
| 7D | 3.3% | 5.1% | 2.3% |
| 1Y | 31.1% | 58.1% | 33.7% |
Avkastning vs industri: CRON presterade sämre än Canadian Pharmaceuticals branschen som gav 58.1 % under det senaste året.
Avkastning vs Marknaden: CRON presterade sämre än Canadian marknaden som gav 33.7 % under det senaste året.
Prisvolatilitet
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 10.4% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 4.0% |
Stabil aktiekurs: CRON har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Canadian.
Volatilitet över tid: CRON s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| n/a | 610 | Mike Gorenstein | thecronosgroup.com |
Cronos Group Inc. är ett cannabinoidföretag som bedriver odling, produktion, distribution och marknadsföring av cannabisprodukter i Kanada, Israel och internationellt. Företaget erbjuder torkade blommor, pre-rolls, oljor, vaporizers, ätbara produkter och cannabistinkturer under varumärkena Spinach, Lord Jones och PEACE NATURALS. Företaget är baserat i Stayner, Kanada.
Cronos Group Inc. Sammanfattning av grunderna
| CRON grundläggande statistik | |
|---|---|
| Börsvärde | CA$1.31b |
| Vinst(TTM) | -CA$12.92m |
| Intäkter(TTM) | CA$200.50m |
7.0x
P/S-förhållande-109.2x
P/E-förhållandeÄr CRON övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CRON resultaträkning (TTM) | |
|---|---|
| Intäkter | US$146.59m |
| Kostnad för intäkter | US$88.19m |
| Bruttovinst | US$58.40m |
| Övriga kostnader | US$67.85m |
| Intäkter | -US$9.45m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.025 |
| Bruttomarginal | 39.84% |
| Nettovinstmarginal | -6.44% |
| Skuld/egenkapitalförhållande | 0% |
Hur har CRON utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/11 20:22 |
| Aktiekurs vid dagens slut | 2026/05/11 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cronos Group Inc. bevakas av 16 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |